Fig. 5

First-line TKI therapy can synergize with sumIL-2 therapy to control cold tumor. a BALB/c mice (n = 5 group) were inoculated subcutaneously with 5 × 10⁵ of TUBO cells and then were i.v. treated with PBS or 10 μg of Erb-sumIL2 on days 10, 13, and 17. b Indicated tumor tissues were collected on day 9 posttumor inoculation. The percentages of CD3⁺ among CD45⁺ cells (left) and CD8⁺ among CD3⁺ cells (right) were analyzed by flow cytometry. c BALB/c mice (n = 3–5 group) were inoculated subcutaneously with 5 × 10⁵ of TUBO cells and then were i.p. treated with PBS or 1 mg of afatinib. TUBO tumor tissues were collected on day 6 post afatinib single treatment. The percentage of CD8⁺ among CD3⁺ cells was analyzed by flow cytometry. d, e BALB/c mice (n = 5 group) were inoculated subcutaneously with 5 × 10⁵ of TUBO cells and then were i.p. treated with PBS or 20 μg of anti-Her2-sumIL2 on either days 12, 15, and 18 or days 25, 28, and 31. For TKI therapy, mice were treated orally with 1 mg of afatinib on days 12 and 17. The tumor growth was measured. f WT BALB/c mice or mice with tumor clearance by afatinib and anti-Her2-sumIL2 were injected subcutaneously with 3 × 10⁶ TUBO cells. The growth of tumor was measured and compared twice a week. Two way ANOVA tests were used to analyze the tumor growth data. Unpaired T-tests were used to analyze the other data. ns (not significant), *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. One of the two or three representative experiments is shown